Fundraising Fox
Theragen
Manassas, US · Founded 2014 · 167 employees on LinkedIn · 1 known investors
Find your way into Theragen
Sign up to see every warm intro you have to Theragen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Theragen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ActaStim offers an FDA-approved electrical bone growth stimulation device used as an adjunct to lumbar spinal fusion surgery to improve fusion success and reduce failure rates. It is a medical device in the orthopedic/spine care category.
Founders & leadership
JC
Jon Christopher McAuliffeExecutive
GG
Gary GrenterPresident, CEO & Co-Founder2014–2017Gary Grenter is an executive with 35 years of experience in sales, marketing, engineering, and operations across medical device companies including Stryker Orthopedics, Kyphon Inc. (which he led to IPO in 2002), Biolectron, SpineAlign Medical, and Spacelabs Healthcare. He holds a B.S. in Production Management from Northern Illinois University and an M.B.A. in Management from the Rochester Institute of Technology.
Board
JA
Jan A. BuckBoard director
KC
Kimball ChenBoard director
AW
Alex W. EvansBoard director
FF
Frithjof FuchsBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$10.4M disclosed across 3 rounds · 2016–2017
▶$1.3MraisedJun 2017 · 2 investors · Other Health CareRule 506(b)
▶$1.3MraisedJun 2017 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kimball ChenDirector
- Jon Christopher McAuliffeExecutive Officer
- Matthew RiceDirector
- Gary GrenterExecutive Officer, Director
- Alex W. EvansDirector
- Offering amount
- $2.3M
- Amount sold
- $1.3M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1.3MraisedFeb 2017 · 2 investors · Other Health CareRule 506(b)
▶$1.3MraisedFeb 2017 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Alex W. EvansDirector
- Matthew RiceDirector
- Gary GrenterExecutive Officer, Director
- Kimball ChenDirector
- Jon Christopher McAuliffeExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $1.3M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$7.9MraisedAug 2016 · 6 investors · Other Health CareRule 506(b)
▶$7.9MraisedAug 2016 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jon Christopher McAuliffeExecutive Officer
- Jan A. BuckDirector
- Kimball ChenDirector
- Alex W. EvansDirector
- Gary GrenterExecutive Officer, Director
- Frithjof FuchsDirector
- Offering amount
- $9.9M
- Amount sold
- $7.9M
- Finders' fees
- $423.6K
- Placement agents
- Source Capital Group, Inc.
- First sale
- Aug 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Theragen.
Frequently asked questions
- What does Theragen do?
- ActaStim offers an FDA-approved electrical bone growth stimulation device used as an adjunct to lumbar spinal fusion surgery to improve fusion success and reduce failure rates. It is a medical device in the orthopedic/spine care category.
- Who are Theragen's investors?
- Theragen's investors include K2 HealthVentures.
- How much funding has Theragen raised?
- Theragen has disclosed $10.4M raised across 3 rounds.
- Where is Theragen headquartered?
- Theragen is headquartered in Manassas, US.